Phenotype of PB T lymphocytes before and after treatment with AMD3100
| Phenotype . | Before AMD3100, mean (± SD) . | 6 h after AMD3100, mean (± SD) . | P . |
|---|---|---|---|
| Total CD3+ count, × 103/mm3 | 1.61 ± 0.35 | 2.23 ± 0.46 | .003 |
| CD3+T lymphocyte populations, %* | |||
| CD4+CD8− | 64.3 ± 17.2 | 67.3 ± 9.5 | NS |
| CD4−CD8+ | 34.1 ± 16.8 | 30.3 ± 9.8 | NS |
| CD4+T lymphocyte subsets, %† | |||
| Naive (CD45RA+CD27+) | 38.7 ± 15.4 | 36.9 ± 16 | NS |
| Cells expressing CD62L, % | 81.8 ± 25 | 78.5 ± 30.1 | NS |
| TEMRA (CD45RA+CD27−) | 2.6 ± 3.3 | 2.0 ± 2.2 | NS |
| Cells expressing CD62L, % | 32 ± 11.4 | 34.3 ± 12.6 | NS |
| TCM (CD45RA−CD27+CD62L+) | 31.4 ± 9.2 | 32.3 ± 9.6 | NS |
| TEMI (CD45RA−CD27+CD62L−) | 18.7 ± 7.7 | 20.9 ± 9.9 | NS |
| TEMII (CD45RA−CD27−) | 8.7 ± 6.6 | 7.9 ± 4.4 | NS |
| Cells expressing CD62L, % | 24.4 ± 10.8 | 23.3 ± 12.2 | NS |
| Treg (FOXP3+CD25+) | 4.6 ± 1.4 | 4.6 ± 1.6 | NS |
| CD8+T lymphocyte subsets, %† | |||
| Naive (CD45RA+CD27+) | 34.4 ± 12.1 | 40.4 ± 11.5 | NS |
| Cells expressing CD62L, % | 62.4 ± 30.3 | 70.5 ± 34.5 | NS |
| TEMRA (CD45RA+CD27−) | 12.5 ± 9 | 8.4 ± 6.2 | NS |
| Cells expressing CD62L, % | 32.4 ± 11.5 | 42.5 ± 18.1 | NS |
| TCM (CD45RA−CD27+CD62L+) | 16.4 ± 8 | 18.8 ± 6 | NS |
| TEMI (CD45RA−CD27+CD62L−) | 29.4 ± 16 | 27.1 ± 12.5 | NS |
| TEMII (CD45RA−CD27−) | 7.3 ± 3.8 | 5.4 ± 3.4 | NS |
| Cells expressing CD62L, % | 26 ± 13.8 | 32.9 ± 8.9 | NS |
| Phenotype . | Before AMD3100, mean (± SD) . | 6 h after AMD3100, mean (± SD) . | P . |
|---|---|---|---|
| Total CD3+ count, × 103/mm3 | 1.61 ± 0.35 | 2.23 ± 0.46 | .003 |
| CD3+T lymphocyte populations, %* | |||
| CD4+CD8− | 64.3 ± 17.2 | 67.3 ± 9.5 | NS |
| CD4−CD8+ | 34.1 ± 16.8 | 30.3 ± 9.8 | NS |
| CD4+T lymphocyte subsets, %† | |||
| Naive (CD45RA+CD27+) | 38.7 ± 15.4 | 36.9 ± 16 | NS |
| Cells expressing CD62L, % | 81.8 ± 25 | 78.5 ± 30.1 | NS |
| TEMRA (CD45RA+CD27−) | 2.6 ± 3.3 | 2.0 ± 2.2 | NS |
| Cells expressing CD62L, % | 32 ± 11.4 | 34.3 ± 12.6 | NS |
| TCM (CD45RA−CD27+CD62L+) | 31.4 ± 9.2 | 32.3 ± 9.6 | NS |
| TEMI (CD45RA−CD27+CD62L−) | 18.7 ± 7.7 | 20.9 ± 9.9 | NS |
| TEMII (CD45RA−CD27−) | 8.7 ± 6.6 | 7.9 ± 4.4 | NS |
| Cells expressing CD62L, % | 24.4 ± 10.8 | 23.3 ± 12.2 | NS |
| Treg (FOXP3+CD25+) | 4.6 ± 1.4 | 4.6 ± 1.6 | NS |
| CD8+T lymphocyte subsets, %† | |||
| Naive (CD45RA+CD27+) | 34.4 ± 12.1 | 40.4 ± 11.5 | NS |
| Cells expressing CD62L, % | 62.4 ± 30.3 | 70.5 ± 34.5 | NS |
| TEMRA (CD45RA+CD27−) | 12.5 ± 9 | 8.4 ± 6.2 | NS |
| Cells expressing CD62L, % | 32.4 ± 11.5 | 42.5 ± 18.1 | NS |
| TCM (CD45RA−CD27+CD62L+) | 16.4 ± 8 | 18.8 ± 6 | NS |
| TEMI (CD45RA−CD27+CD62L−) | 29.4 ± 16 | 27.1 ± 12.5 | NS |
| TEMII (CD45RA−CD27−) | 7.3 ± 3.8 | 5.4 ± 3.4 | NS |
| Cells expressing CD62L, % | 26 ± 13.8 | 32.9 ± 8.9 | NS |
TEMRA, CD45RA-expressing effector memory T cells; TCM, central memory T cells; TEMI, effector memory type I T cells; TEMII, effector memory type II T cells; Treg, regulatory T cell; and NS, not significant.
As a percentage of the total CD3+ T lymphocyte population.
As a percentage of the total CD4+ or CD8+ T lymphocyte population.